Costs Incurred by Patients Undergoing Advanced Colorectal Cancer Therapy

Mark Sculpher, Michael Palmer and Anne Heyes

PharmacoEconomics, 2000, vol. 17, issue 4, 370 pages

Abstract: Background: To assess the cost effectiveness of healthcare interventions from a societal perspective, it is necessary to include costs such as patients’ travel costs and the opportunity cost of patients’ time spent consuming healthcare. Objective: To analyse patients’ travel and time costs associated with 2 alternative drug therapies for advanced colorectal cancer: raltitrexed and fluorouracil plus folinic acid (leucovorin) [5FU + FA]. Design and setting: The analysis is based on a prospective substudy within a multinational randomised controlled trial of raltitrexed versus 5FU + FA. Patients and participants: 495 patients with advanced colorectal cancer were enrolled in the trial, 270 of whom completed the questionnaire on costs. Methods: Data were collected within the trial to estimate the numbers of journeys made to and from hospital by patients and the time lost from usual activities over the period of therapy. A subset of patients were asked to complete a questionnaire to provide the information necessary to value time and travel costs in monetary terms. These data, together with UK transport costs and forgone time values, were used to value the transport and opportunity costs of time of all patients in the trial. Results: The total travel cost per patient was statistically significantly higher in the 5FU + FA group (p > 0.001; median of £31.50 with raltitrexed, £96.00 with 5FU + FA; 1997 prices). Overall time cost per patient was also higher in the 5FU + FA group (p=0.005; median of £168.80 with raltitrexed, £224.04 with 5FU + FA). Adding the two gives a median total cost per patient of £206.08 [interquartile range (IQR) £108 to £482] among patients randomised to raltitrexed and £342.25 (IQR £214 to £555) for those in the 5FU + FA group (p > 0.001). The sensitivity analysis showed that, even under extreme assumptions, raltitrexed imposed fewer time and travel costs on patients. These cost differences are likely, in part, to reflect the longer treatment times for 5FU + FA patients (median 16.9 vs 12.7 weeks). Conclusions: Different chemotherapy regimens for advanced colorectal cancer can impose different travel and time costs on patients. Over the period of treatment in a randomised controlled trial of 495 patients, those randomised to 5FU + FA were found to have a median travel plus time cost £136 per patient higher than those randomised to raltitrexed. Copyright Adis International Limited 2000

Date: 2000
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://hdl.handle.net/10.2165/00019053-200017040-00006 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:17:y:2000:i:4:p:361-370

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.2165/00019053-200017040-00006

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().